Business Context and Reporting Period
This Form 8-K Current Report was filed by Protara Therapeutics, Inc. on January 30, 2023. The filing discloses the appointment of Patrick Fabbio as the Company's Chief Financial Officer (CFO), effective January 30, 2023. Mr. Fabbio replaces Jesse Shefferman, the President and CEO, who had been serving as the interim CFO.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the leadership transition within the finance function:
- Appointment: Patrick Fabbio appointed as CFO and Principal Financial Officer.
- Departure: Jesse Shefferman ceases serving as interim CFO, though he remains President and CEO.
- Continuity: Hannah Fry remains the Company's Controller and Principal Accounting Officer.
Compensation, Outlook, and Risks
The filing details the terms of Mr. Fabbio's Executive Employment Agreement, dated January 5, 2023:
- Base Salary: $445,000 annually.
- Bonus: Annual discretionary cash bonus of 45% of base salary.
- Signing Bonus: One-time payment of $25,000.
- Equity Grant: Stock option to purchase 300,000 shares of common stock at the closing price on January 30, 2023. The option vests over four years (25% on the first anniversary, with the remainder vesting monthly).
- Severance: In the event of termination without cause or resignation for good reason, Mr. Fabbio is entitled to nine months of base salary, twelve months of target bonus, and nine months of healthcare/benefit premium reimbursement, subject to a general release.
- Change in Control: If terminated other than for cause, death, or disability within 12 months of a change in control, Mr. Fabbio receives 100% acceleration of unvested equity and twelve months of base salary in lieu of the standard severance cash payment.
The filing does not provide specific guidance, outlook, or risk factors beyond the standard disclosure regarding the employment agreement terms.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 300,000 share option grant in the Company's 2020 Inducement Plan.
- Confirm the exact closing share price on January 30, 2023, to determine the strike price of the new option grant.
- Review the full Executive Employment Agreement (expected as an exhibit to the Q1 2023 Form 10-Q) for detailed termination conditions.
- Monitor future filings for any impact on the Company's cash burn rate due to the new executive compensation structure.